US Edition
Ascletis Begins Dosing in Phase IIa Trial of ASC30 for Obesity Treatment
- Ascletis Pharma announced on July 2, 2025, that it dosed first participants in a U.S. multi-center 13-week Phase IIa trial of oral GLP-1 receptor agonist ASC30 for obesity treatment.
- This trial follows earlier Phase Ia and Ib studies showing ASC30's tolerability and up to 6.5% placebo-adjusted weight reduction over four weeks, with screening started in June 2025.
- The randomized, double-blind, placebo-controlled study enrolls adults with BMI ≥30 kg/m² or overweight with weight-related comorbidities, using a slow titration to maintenance doses up to 60 mg weekly.
- Ascletis CEO Jinzi Jason Wu stated, “We are ahead of schedule” and expects topline Phase IIa data in the fourth quarter of 2025; ASC30 has patent protection until 2044.
- If approved, ASC30 could offer a once-daily oral treatment option for obesity, complementing existing FDA-approved injectable GLP-1 receptor agonists and advancing metabolic disease therapeutics.
53 Articles
53 Articles
LoudounTimes.com
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small molecule oral GLP-1 receptor agonist ASC30.
Ascletis begins dosing in Phase IIa trial of ASC30 for obesity treatment
Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.The post Ascletis begins dosing in Phase IIa trial of ASC30 for obesity treatment appeared first on Clinical Trials Arena.
First participants dosed in Ascletis’ 13-week Phase IIa study of oral GLP-1r agonist ASC30
The first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in Ascletis Pharma’s US 13-week Phase IIa study of small molecule oral GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity. ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection admin…
A novel oral medication that mimics the effect of gastric bypass surgery shows promising results for safe weight loss and maintenance of muscle mass in initial studies.
Coverage Details
Bias Distribution
- 63% of the sources are Center
To view factuality data please Upgrade to Premium
